BiotechTube

Placebo + Januvia

Phase 2Terminated
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Glucose Homeostasis

Conditions

Glucose Homeostasis

Trial Timeline

Mar 1, 2009 → Mar 1, 2010

NCT ID
NCT00947011

About Placebo + Januvia

Placebo + Januvia is a phase 2 stage product being developed by Merck for Glucose Homeostasis. The current trial status is terminated. This product is registered under clinical trial identifier NCT00947011. Target conditions include Glucose Homeostasis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT00947011Phase 2Terminated

Competing Products

17 competing products in Glucose Homeostasis

See all competitors
ProductCompanyStageHype Score
Aspirin + Alpha lipoic acid + Olmesartan + PlaceboDaiichi SankyoPre-clinical
23
Exenatide + MetforminEli LillyApproved
85
AZD1656AstraZenecaPhase 1
33
Candesartan + PlaceboAstraZenecaApproved
85
Placebo for Sitagliptin 25 mg + Placebo for Sitagliptin 50 mg + Sitagliptin 25 mg + Sitagliptin 50 mgMerckPhase 2
52
Sitagliptin-Metformin + Metformin + Placebo pillMerckApproved
85
Comparator: exenatide + Comparator: exenatide + Comparator: PlaceboMerckPhase 1
33
cyclosporine micro-emulsionNovartisApproved
85
Ramipril + RosiglitazonePfizerPhase 3
76
HSK7653 10mg Q2W + HSK7653 25mg Q2W + PlaceboHaisco Pharmaceutical GroupPhase 2
49
TriheptanoinUltragenyx PharmaceuticalPre-clinical
18
UX007Ultragenyx PharmaceuticalPhase 2
47
UX007 + PlaceboUltragenyx PharmaceuticalPhase 3
72
TriheptanoinUltragenyx PharmaceuticalPhase 2
47
TriheptanoinUltragenyx PharmaceuticalPhase 2
47
UX007 + PlaceboUltragenyx PharmaceuticalPhase 2
47
GFT505 80mg + PlaceboGenfitPhase 2
44

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85